ReviewFrontiers in oncology2022

Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials.

Linwei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.